In conclusion, the findings of this study deepen our understanding of HER2-low immunobiology and prompt consideration of HER2 heterogeneity as a non-negligible factor for developing immunotherapy in patients with HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.